Swiss Pharma & Manufacturing: Lonza lifted its full-year core profit margin target to 33–34%, citing strong execution and maturing projects, while also staying on track to focus on contract drug manufacturing after selling capsules/health ingredients. Generic Drug Policy Shock: Sandoz said it will keep talking with US policymakers after Trump’s tariff threat aimed at forcing more domestic generic production. Biotech Supply Chain: ImmuPharma picked Thermo Fisher to manufacture its diabetes drug candidate Kapiglucagon, completing key manufacturing partners. Industrial Automation: ABB won a contract to modernise Australia’s Pelican Point power station control system, boosting cyber security and real-time monitoring. Rail Infrastructure: Swiss firm Wyss&Lila opened a rolling stock maintenance workshop in Rijeka, positioning the Adriatic port as a maintenance hub for freight corridors. Energy & Climate Tech: A Swiss-linked BIPV guidebook project (with Sun Appeal and SUPSI) targets faster building-integrated solar adoption, while EU UPLIFT backs new drilling tech to unlock more reliable deep geothermal heat. Swiss Work & Society: A Swiss motion would raise the legal minimum holiday from four to five weeks, with employers warning of higher labour costs. Food Security Politics: A new Swiss initiative would push plant-based production and consumption to raise self-sufficiency, with voters deciding on 27 September.